Next Article in Journal
Suramin Targets the Conserved Ligand-Binding Pocket of Human Raf1 Kinase Inhibitory Protein
Previous Article in Journal
The Effect of the Reducing Sugars in the Synthesis of Visible-Light-Active Copper(I) Oxide Photocatalyst
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 4
10.3390/molecules26041150
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents

by
Nana Meng
1,2,†,
Shuyan Zhou
1,†,
Min Hu
3,
Youzhi Xu
1,
Yong Xia
1,
Xiuxiu Zeng
1 and
Luoting Yu
1,*
1
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China
2
Hairong Research Institute, Sichuan Hairong Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group, Chengdu 611830, China
3
Open Laboratory, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu 610041, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2021, 26(4), 1150; https://doi.org/10.3390/molecules26041150
Submission received: 25 January 2021 / Revised: 15 February 2021 / Accepted: 19 February 2021 / Published: 21 February 2021
Browse Figures
Versions Notes

Abstract

:
A novel series of 4-(4-formamidophenylamino)-N-methylpicolinamide derivatives were synthesized and evaluated against different tumor cell lines. Experiments in vitro showed that these derivatives could inhibit the proliferation of two kinds of human cancer cell lines (HepG2, HCT116) at low micromolar concentrations and the most potent analog 5q possessed broad-spectrum antiproliferative activity. Experiments in vivo demonstrated that 5q could effectively prolong the longevity of colon carcinoma-burdened mice and slow down the progression of cancer cells by suppression of angiogenesis and the induction of apoptosis and necrosis.

1. Introduction

Cancer is one of the most common causes of death and its incidence is increasing worldwide [1]. Deregulated proliferation and inhibition of apoptosis lie at the heart of all tumor development, so they present two obvious targets for therapeutic intervention in all cancers [2,3]. In addition, angiogenesis plays a pivotal role in the progression of cancerous cells [4,5,6]. According to the opinion of Folkman, the growth and metastasis of neoplasms depend on new blood vessels. The diameter of neoplasms cannot exceed 2 mm without the support of new blood vessels. Therefore, the targeting of cancerous blood vessels is becoming a hot topic in the development of new drugs [7,8,9,10,11,12,13].
The findings mentioned above suggested that angiogenesis inhibitors and apoptosis inducers could have antitumor effects, and many angiogenesis inhibitors and apoptosis inducers were subsequently developed. Sorafenib, the first oral multikinase inhibitor to target Raf and that affects tumor signaling and the tumor vasculature, was approved by the FDA for the treatment of advanced renal cell carcinoma in December 2005 [14]. Axitinib, an oral angiogenesis inhibitor, was reported to be effective in a clinical trial [15]. Many other angiogenesis inhibitors were also developed, such as Enzastaurin [16], Sunitinib [17], Nilotinib [18], as well as Lapatinib [19]. Therefore, angiogenesis inhibitors and apoptosis inducers are promising agents in the exploitation and development of anticancer medicines.
Our laboratory has a long-standing interest in the design, synthesis, and biological evaluation of novel tumor growth inhibitors, angiogenesis inhibitors, and apoptosis inducers as potential new anticancer agents [20,21,22]. In a previous cell-based screening of anticancer drugs, we found an active structure: 4-(4-formamidophenylamino)-N-methyl picolinamide [23,24]. Based on this special structure, we designed and synthesized a series of new compounds (5a–v). These derivates were evaluated against different tumor cell lines by MTT assay. Experiments in vitro showed that most of the derivatives could inhibit the proliferation of two kinds of human cancer cell lines (HepG2, HCT116) at low micromolar concentrations in a dose-dependent manner. Preliminary structure–activity relationships were put forward based on the biological results. Compound 5q was a promising agent, which significantly inhibited colon cancer growth in vivo with the suppression rate ranging from 70% to 90%. Inhibition of angiogenesis and apoptosis of cancer cells were also observed. The results suggest that 5q is a potential new small-molecule antitumor agent in chemotherapy for colon carcinoma. Further structural optimization and mechanism studies are worth pursuing.

2. Results

2.1. Chemistry

The novel 4-(4-formamidophenylamino)-N-methylpicolinamide derivatives (5a–v) were prepared according to the general synthetic strategy illustrated in Scheme 1 [23,24]. One of the key intermediates, 4-(4-aminophenylamino)-N-methylpicolinamide 4a, was prepared as follows: commercially available 2-picolinic acid was reacted with thionyl chloride and subsequently treated with methylamine to give 3, which was heated with 4-amino-N-methylbenzamide at 160 °C with no solvent. The reaction mixture was dissolved in EtOH and concentrated HCl, then treated with 1% NaOH aqueous solution to yield 4a. The other key intermediate 4b was synthesized according to known methods [25,26,27]. With the key intermediates 4a and 4b in hand, derivatives 5a–i were prepared through condensation of 4a with aromatic isocyanates, which were easily gained via the treatment of substituted aniline or cyclohexylamine with triphosgene, in the presence of triethylamine. Using the same synthetic strategy, derivatives 5j–v were prepared through acylation of 4a or 4b with a series of substituted benzoyl chloride compounds. The structures of 5a–v were fully characterized by 1H-NMR, 13C-NMR, and ESI-MS analysis.

2.2. Pharmacology

2.2.1. In Vitro Anticancer Activities

Anticancer activities of derivatives 5a–v against HepG2 (Human Liver Cancer) and HCT116 (Human Colon Carcinoma) cell lines were determined by MTT assay, and the results expressed as IC50 are summarized in Table 1. As can be seen from the results, some derivatives (such as 5q) exhibited potent antiproliferation activities as significant as Sorafenib against some cell lines.
Replacement of the amide linkage with urea linkage yielded compounds 5a–i. As shown in Table 1, the introduction of urea linkage to the benzene ring will slightly increase the inhibitory activity (compare 5a–i with 5j–n).
Based on the isostere principle, the NH group was replaced with oxygen, yielding compounds 5o–v. As shown in Table 1, the introduction of a meta substituent on the phenyl ring such as lipophilic and bulky groups would strikingly increase inhibitory activity (5q) in vitro.

2.2.2. In Vivo Antitumor Effects

Based on the cytotoxic activities of the tested compounds in vitro, compound 5q was chosen to investigate its growth inhibitory activity against the mice tumor model of colon cancer CT26 in Balb/c mice. When the tumor became palpable about 10 days after subcutaneous inoculation into the right flank of Balb/c mice, 5q was administered orally once daily at a dosage of 75 mg/kg. The suppression of neoplasm was obvious in the curve because the average volumes of tumors in the 5q-treated group were much smaller than that of the control group (p < 0.05) (Figure 1A). With the suppression rate ranging from 70% to 90%, the histological appearance of apoptotic and necrotic cells in the H.E. sections of the treated group verified the effectiveness of 5q in the anticancer activity (Figure 1B). In particular, we observed that some neoplasms became black and sclerotic, finally resulting in shrinkage and exfoliation in the late stage of treatment, which suggested that large apoptosis and necrosis existed. Benefiting from the suppression of cell proliferation, the consequent prolongation of life span in the treated group was reasonable (Figure 1C).

2.2.3. Apoptosis and Anti-Angiogenesis Effect

Observation of the pathology of the mice after 2 weeks treated with 5q or control was conducted. The apoptosis of cancer cells was measured by TUNEL assay. Compared to the scattered positive signals in the control group, clustered positive signals in the 5q-treated group strongly reflected the induction of apoptosis by the interference of 5q (Figure 2A,B). Inhibition of angiogenesis was also observed. The vessel density was measured with CD31 immunohistochemistry in the frozen sections. More than a 50% decrease in vessel density could be seen in the 5q-treated group compared to the control (Figure 2C,D).

3. Materials and Methods

3.1. Chemistry

All materials and reagents were obtained from commercial sources and were used without further purification unless stated. Melting points were determined on a SGW X-4 microscopic melting point (Shanghai Precision and Scientific Instrument Co., Ltd., Shanghai, China). 1H-NMR and 13C-NMR spectra were recorded on a Bruker Varian Unity Inova-400 (400/100 MHz) spectrometer (Bruker Corporation, Billerica, MA, USA) using TMS as the internal reference chemical. Shifts are expressed as δ values in ppm. Mass spectra were carried out on a triple-quadrupole mass spectrometry system from Waters Quattro PremierTM/XE (Waters Corporation, Milford, MA, USA). FT-IR spectra were recorded on a Nicolet 6700 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).

3.1.1. Synthesis of 4-Chloro-N-methylpicolinamide (3)

The compound was prepared according to the known method [25,26].

3.1.2. Synthesis of 4-(4-Aminophenylamino)-N-methylpicolinamide (4a)

A mixture of 3 (10.4 g, 61.2 mmol) and 4-amino-N-methylbenzamide (9.01 g, 60 mmol) was heated at 160 °C for 1 h. The reaction mixture was dissolved in EtOH (228 mL) and concentrated HCl (45.7 mL) was added dropwise. The solution was stirred under reflux for 4 h and cooled to room temperature. The resulting solid was collected by filtration, washed with EtOH, and dried. The precipitate was suspended in 1% NaOH aqueous solution (385 mL) and stirred for 30 min. Then, the solid was collected by filtration, crystallized by EtOH, and decolorized with activated carbon to afford 4a as a white solid (yield 91.2%). 1H-NMR (400 MHz, DMSO-d6) δ: 2.76 (3H, d, J = 4.4 Hz, CH3), 5.05 (2H, s, NH2), 6.59 (2H, d, J = 8.4 Hz, Ar-H), 6.71 (1H, dd, J = 5.6, 2.4 Hz, Ar-H), 6.87 (2H, d, J = 8.4 Hz, Ar-H), 7.31 (1H, d, J = 2.4 Hz, Ar-H), 8.07 (1H, d, J = 5.6 Hz, Ar-H), 8.50 (1H, s, Ar -NH-Ar), 8.57 ppm (1H, q, NHCH3). 13C-NMR (100 MHz, DMSO-d6) δ: 26.3, 106.2, 109.6, 115.1 (2C), 125.2 (2C), 128.4, 146.5, 149.0, 151.1, 154.2, 165.4 ppm. ESI-MS: m/z 243.26 [M + H+].

3.1.3. Synthesis of 4-(4-Aminophenoxy)-N-methylpicolinamide (4b)

The compound was prepared according to the reported method [27].

3.1.4. General Procedure for Synthesizing of 5a–i

To a solution of triphosgene (5 mmol) in CH2Cl2 (10 mL), substituted aniline or cyclohexylamine (5.5 mmol) was added dropwise in CH2Cl2 (10 mL) followed by the drop wise addition of triethylamine (1.6 mL) in CH2Cl2 (10 mL). The mixture was stirred for 30 min. The solvent was removed on a rotary evaporator. The resulting residue was dissolved in CH2Cl2 (10 mL), and 4a (5 mmol) in CH2Cl2 (10 mL) was added. After the mixture was refluxed for 1h and cooled to room temperature, the resulting solid was collected by filtration and crystallized by EtOH.
N-methyl-4-(4-(3-phenylureido) phenylamino) picolinamide (5a), Yield 63.2%; mp 176 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.82 (3H, d, J = 4.8 Hz, CH3), 6.94–6.98 (1H, m, Ar-H), 7.08 (1H, q, Ar-H), 7.26–7.30 (4H, m, Ar-H), 7.47 (2H, d, J = 7.2 Hz, Ar-H), 7.52 (1H, d, J = 2.4 Hz, Ar-H), 7.59 (2H, d, J = 8.8 Hz, Ar-H), 8.18 (1H, d, J = 6.8 Hz, Ar-H), 9.22 (1H, s, NHCONH), 9.29 (1H, q, NHCH3), 9.42 (1H, s, NHCONH), 10.51 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 26.3, 105.9, 109.8, 117.9 (2C), 118.9 (2C), 121.7, 124.2 (2C), 128.7 (2C), 130.7, 138.3, 139.8, 141.7, 143.5, 152.7, 156.4, 160.4 ppm; ESI-MS: m/z 360.21 [M − H+].
N-methyl-4-(4-(3-(3-(trifluoromethyl) phenyl) ureido) phenylamino) picolinamide (5b), Yield 85.2%; mp 186–190 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.82 (3H, d, J = 4.0 Hz, CH3), 7.09 (1H, s, Ar-H), 7.30 (3H, d, J = 8.4 Hz, Ar-H), 7.50–7.54 (2H,m, Ar-H), 7.60(3H, d, J = 8.8 Hz, Ar-H), 8.01 (1H, s, Ar-H), 8.18 (1H, d, J = 6.8 Hz, Ar-H), 9.34 (1H, s, NHCH3), 9.64 (1H, s, NHCONH), 9.81 (1H, s, NHCONH), 10.65 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 26.8, 56.5, 114.2, 114.2, 118.4, 119.6 (2C), 121.9, 123.3, 124.9 (2C), 126.0, 129.6, 129.9, 130.4, 131.1, 138.7, 141.2, 143.1, 153.2, 157.5, 160.2 ppm; ESI-MS: m/z 430.3 [M + H+].
4-(4-(3-(3-fluorophenyl) ureido) phenylamino)-N-methylpicolinamide (5c), Yield 80.3%; mp 224–226 °C; light green solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.8278 (3H, d, J = 4.0Hz, CH3), 6.76–6.80 (1H, m, Ar-H), 6.92 (1H, dd, J = 5.6, 2.4 Hz, Ar-H), 7.11–7.18 (3H, m, Ar-H), 7.28–7.33 (1H, m, Ar-H), 7.46–7.52 (4H, m, Ar-H), 8.17 (1H, d, J = 5.6 Hz, Ar-H), 8.62 (1H, q, NHCH3), 8.75 (1H, s, NHCONH), 8.91 (1H, s, NHCONH), 8.92 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 25.8, 104.9, 106.4, 107.9, 109.7, 113.8, 119.6 (2C), 122.3 (2C), 130.2, 134.1, 135.4, 141.6, 148.7, 150.8, 152.3, 161.6, 163.2, 164.7 ppm; ESI-MS: m/z 378.2 [M − H+].
4-(4-(3-(3-chlorophenyl) ureido) phenylamino)-N-methylpicolinamide (5d), Yield 84.0%; mp 182 °C; yellow solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 6.97 (1H, dd, J = 6.0, 2.4 Hz, Ar-H), 6.99–7.02 (1H, m, Ar-H), 7.19 (2H, d, J = 8.8Hz, Ar-H), 7.26–7.32 (2H, m, Ar-H), 7.49–7.52 (3H, m, Ar-H), 7.72 (1H, d, J = 2.4 Hz, Ar-H), 8.17 (1H, d, J = 6.0 Hz, Ar-H), 8.83 (1H, q, NHCH3), 9.05 (1H, s, NHCONH), 9.15 (1H, s, NHCONH), 9.42 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 19.0, 26.9, 56.5, 116.8, 117.6, 119.5 (2C), 121.8, 124.9 (2C), 130.9 (2C), 131.0, 133.7, 138.7, 141.8, 143.0, 153.0, 157.4, 160.2 ppm; ESI-MS: m/z 396.19 [M + H+].
4-(4-(3-(3-bromophenyl) ureido) phenylamino) -N-methylpicolinamide (5e), Yield 89.0%; mp 182 °C; yellow solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.82 (3H,d, J = 4.8 Hz, CH3), 7.00–7.02 (1H, m, Ar-H), 7.11 (1H, s, Ar-H), 7.29–7.33 (4H, m, Ar-H), 7.52 (1H, d, J = 2.8 Hz, Ar-H), 7.59 (2H,d, J = 8.8 Hz, Ar-H),7.71–7.72 (1H, m, Ar-H), 8.18 (1H, d, J = 6.8 Hz, Ar-H), 9.39 (1H, q, NHCH3), 9.63 (1H, s, NHCONH), 9.66 (1H, s, NHCONH), 10.74 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 19.0, 26.9, 56.5, 116.7, 117.6,119.5 (2C), 121.8, 124.9 (2C), 130.9 (2C), 131.0, 133.7, 138.7, 141.8, 143.0, 153.0, 157.4, 160.2 ppm; ESI-MS: m/z 440.36 [M + H+].
N-methyl-4-(4-(3-(3- nitrophenyl) ureido) phenylamino) picolinamide (5f), Yield 91.0%; mp 220 °C; brown solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.82 (3H, d, J = 4.4 Hz, CH3), 7.12 (1H, q, Ar-H), 7.31 (2H, d, J = 8.8 Hz, Ar-H), 7.53 (1H, d, J = 2.4 Hz, Ar-H), 7.56 (1H, d, J = 8.0 Hz, Ar-H), 7.59–7.63 (2H, m, Ar-H), 7.71–7.74 (1H, m, Ar-H), 7.81–7.83 (1H, m, Ar-H), 8.18 (1H, d, J = 6.8 Hz, Ar-H), 8.56–8.58 (1H, m, Ar-H), 9.38 (1H, q, NHCH3), 9.74 (1H, s, NHCONH), 10.05 (1H, s, NHCONH), 10.75 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 26.4, 111.7, 112.2, 116.2, 119.2 (2C), 123.9, 124.4 (2C), 130.1, 130.8, 131.3, 138.0, 141.1, 142.3, 148.1, 152.6, 156.8, 159.8, 160.4 ppm; ESI-MS: m/z 405.1 [M − H+].
4-(4-(3-(3-methoxyphenyl) ureido) phenylamino)-N-methylpicolinamide (5g), Yield 57.5%; mp176 °C; yellow solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.82 (3H, d, J = 4.4 Hz, CH3), 3.73 (3H, s, OCH3), 6.55 (1H, dd, J = 8.0, 2.4 Hz, Ar-H), 6.95 (1H, dd, J = 8.0, 1.2 Hz, Ar-H), 7.12–7.16 (1H, m, Ar-H), 7.19 (1H, d, J = 8.0 Hz, Ar-H), 7.21–7.22 (1H, m, Ar-H), 7.29 (2H, d, J = 8.8 Hz, Ar-H), 7.53 (1H, d, J = 2.4 Hz, Ar-H), 7.60 (2H, d, J = 8.8 Hz, Ar-H), 8.18 (1H, d, J = 6.8 Hz, Ar-H), 9.35 (1H, s, NHCONH), 9.39 (1H, q, NHCH3), 9.55 (1H, s, NHCONH), 10.75 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 18.5, 26.4, 48.5, 54.9, 56.0, 103.7, 107.0, 110.3, 118.9 (2C), 124.4 (2C), 129.5, 130.3, 138.6, 141.0, 142.5, 152.6, 157.0, 159.6, 159.7 ppm; ESI-MS: m/z 390.21 [M + H+].
4-(4-(3-(4-chloro-3-(trifluoromethyl) phenyl) ureido) phenylamino)-N-methylpicolinamide (5h), Yield 92.3%; mp 223–225 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.82 (3H, d, J = 4.4 Hz, CH3), 7.11 (1H, s, Ar-H), 7.31 (2H, d, J = 8.8 Hz, Ar-H), 7.53 (1H, d, J = 2.4 Hz, Ar-H), 7.59–7.67 (4H, m, Ar-H), 8.12 (1H, d, J = 2.4 Hz, Ar-H), 8.18 (1H, d, J = 6.8 Hz, Ar-H), 9.36 (1H, s, NHCH3), 9.66 (1H, s, NHCONH), 9.95 (1H, s, NHCONH), 10.70 ppm (1H, br s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 26.3,116.2, 116.2, 119.2 (2C), 121,4, 122.1, 122.5, 124.1, 124.4 (2C), 126.9, 130.8, 132.0, 138.0, 139.4, 140.7, 142.5, 152.5, 156.9, 159.7 ppm; ESI-MS: m/z 464.14 [M + H+].
4-(4-(3-cyclohexylureido) phenylamino)-N-methylpicolinamide (5i), Yield 70.5%; mp 236–240 °C; yellow solid; 1H-NMR (400 MHz, DMSO-d6) δ: 1.12–1.22 (3H, m, cyclohexane-H), 1.27–1.35 (2H, m, cyclohexane-H), 1.53–1.56 (1H, m, cyclohexane-H), 1.65–1.68 (2H, m, cyclohexane-H), 1.81 (2H, d, J = 9.6 Hz, cyclohexane-H), 2.78 (3H, d, J = 4.8 Hz, CH3), 3.46–3.47 (1H, m, cyclohexane-H), 6.05(1H, d, J = 7.6Hz, Ar-H), 6.86–6.87 (1H, m, Ar-H), 7.08 (2H, d, J = 8.4 Hz, Ar-H), 7.39 (2H, d, J = 8.4 Hz, Ar-H), 7.40 (1H, s, NHCONH), 8.14 (1H, d, J = 5.2 Hz, Ar-H), 8.31(1H, s, NHCONH), 8.61(1H, q, NHCH3), 8.81 ppm (1H, s, Ar-NH-Ar); 13C-NMR (100 MHz, DMSO-d6) δ: 24.8 (2C), 25.7, 26.3, 33.5 (2C), 48.1, 106.8, 110.0, 119.0 (2C), 123.1 (2C), 133.4, 137.3, 149.2, 151.2, 153.0, 154.9, 165.2 ppm; ESI-MS: m/z 366.3 [M − H+].

3.1.5. General Procedure for Synthesizing of 5j–n

To the suspension of anhydrous potassium carbonate (1.64 g, 12.5 mmol) and 4a (1.22 g, 5 mmol) in THF (11.4 mL), substituted benzoyl chloride (7.5 mmol) was added dropwise. After being stirred at room temperature for 2 h, the mixture was extracted by ethyl acetate and water; then, the combined organic layers were dried over anhydrous Na2SO4 and concentrated under vacuum, and recrystallized by ethanol to give the resulting solids.
N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenylamino) picolinamide (5j), Yield 81.2%; mp 204–205 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 6.99 (1H, dd, J = 5.2, 2.0 Hz, Ar-H), 7.23 (2H, d, J = 8.8 Hz, Ar-H), 7.55(1H, d, J = 1.2Hz, Ar-H), 7.78–7.81(3H, m, Ar-H), 7.97 (1H, m, Ar-H), 8.20 (1H, d, J = 5.6 Hz, Ar-H), 8.27–8.30 (2H, m, Ar-H), 8.63 (1H, q, NHCH3), 9.03 (1H, s, Ar-NH-Ar), 10.50 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.3, 107.2, 110.5, 121.9 (2C), 122.1 (2C), 124.7, 124.7, 125.8, 128.5, 130.1, 132.2, 134.9, 136.3, 136.4, 149.4, 151.4, 152.4, 164.3, 165.2 ppm; ESI-MS: m/z 415.2 [M + H+].
4-(4-(3- fluorobenzamido) phenylamino)-N-methylpicolinamide (5k), Yield 51.2%; mp 216–218 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 6.99 (1H, q, Ar-H), 7.22 (2H, d, J = 8.8 Hz, Ar-H), 7.44–7.48 (1H, m, Ar-H), 7.54 (1H, d, J = 1.6 Hz, Ar-H), 7.57–7.59 (1H, m, Ar-H), 7.77–7.83 (4H, m, Ar-H), 8.20 (1H, d, J = 5.6 Hz, Ar-H), 8.63 (1H, q, NHCH3), 9.01 (1H, s, Ar-NH-Ar), 10.34 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 25.9, 106.7, 109.9, 121.4 (2C), 121.6 (2C), 130.5, 130.5, 134.5, 135.8, 137.2, 137.3, 148.9, 150.9, 151.9, 161.1, 162.7, 163.9, 164.7 ppm; ESI-MS: m/z 362.94 [M − H+].
4-(4-(3- chlorobenzamido) phenylamino) -N-methylpicolinamide (5l), Yield 50.2%; mp 202–204 °C; light green solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 5.2 Hz, CH3), 6.99 (1H, dd, J = 5.6, 2.4 Hz, Ar-H), 7.22 (2H, d, J = 8.4 Hz, Ar-H), 7.54–7.60 (2H, m, Ar-H), 7.66–7.68 (1H, m, Ar-H),7.78 (2H, d, J = 8.4 Hz, Ar-H), 7.92 (1H, d, J = 8.0 Hz, Ar-H), 8.01 (1H, s, Ar-H), 8.20 (1H, d, J = 5.6 Hz, Ar-H), 8.64 (1H, q, NHCH3), 9.02 (1H, s, Ar-NH-Ar), 10.38 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 25.9, 106.7, 109.9, 121.5 (2C), 121.6 (2C), 126.4, 127.3, 130.3, 131.3, 133.2, 134.5, 135.8, 136.9, 148.9, 150.8, 151.9, 163.8, 164.7 ppm; ESI-MS: m/z 381.15 [M + H+].
N-methyl-4-(4- (3- nitrobenzamido) phenylamino) picolinamide (5m), Yield 92.0%; mp 258–260 °C; yellow solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3),7.00 (1H, dd, J = 5.6, 2.4 Hz, Ar-H), 7.25 (2H, d, J = 8.8 Hz, Ar-H), 7.55 (1H, d, J = 2.4 Hz, Ar-H), 7.80 (2H, d, J = 8.8 Hz, Ar-H), 7.86 (1H, t, J = 8.0 Hz, Ar-H), 8.21 (1H, d, J = 5.6 Hz, Ar-H), 8.41–8.46 (2H, m, Ar-H), 8.64 (1H, q, NHCH3), 8.80 (1H, s, Ar-H), 9.04 (1H, s, Ar-NH-Ar), 10.62 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 25.9, 106.8, 110.0, 121.4 (2C), 121.7 (2C), 122.3, 126.0, 130.1, 134.1, 134.2, 136.0, 136.3, 147.7, 148.9, 150.9, 151.8, 163.0, 164.7 ppm; ESI-MS: m/z 390.10 [M − H+].
4-(4- (3-methoxybenzamido) phenylamino) -N-methylpicolinamide (5n), Yield 86.0%; mp 169 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 3.85 (3H, s, OCH3), 6.98 (1H, q, Ar-H), 7.15–7.18 (1H, m, Ar-H), 7.22 (2H, d, J = 8.8 Hz, Ar-H), 7.44–7.50 (2H, m, Ar-H), 7.54–7.56 (2H, m, Ar-H), 7.79 (2H, d, J = 8.8 Hz, Ar-H), 8.20 (1H, d, J = 5.6 Hz, Ar-H), 8.64 (1H, q, NHCH3), 9.01 (1H, s, Ar-NH-Ar), 10.25 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 25.9, 55.3, 106.7, 109.9, 112.9, 117.2, 119.8, 121.5 (2C), 121.6 (2C), 129.5, 134.8, 135.6, 136.4, 148.9, 150.9, 151.9, 159.2, 174.7, 165.0 ppm; ESI-MS: m/z 375.14 [M − H+].

3.1.6. General Procedure for Synthesizing of 5o–v

To the suspension of anhydrous potassium carbonate (1.64 g, 12.5 mmol) and 4b (1.22 g, 5 mmol) in THF (11.4 mL), substituted benzoyl chloride (7.5 mmol) was added dropwise. After being stirred at room temperature for 2 h, the mixture was extracted by ethyl acetate and water; then, the combined organic layers were dried over anhydrous Na2SO4 and concentrated under vacuum, and recrystallized by ethanol to give the resulting solids. In order to improve the solubility and bioavailability of compound 5q, we prepared 5q·TsOH by the following steps: To the suspension of 5q (10.4 mmol) in ethyl acetate (47 mL) at 70 °C, p-toluenesulfonic acid (11.7 mmol) in a mixture of ethyl acetate (15 mL) and water (2 mL) was added dropwise. The solution was stirred at 70 ℃ for 2 h and cooled to room temperature. The resulting solid was collected by filtration, washed with ethyl acetate, and dried to afford 5q·TsOH as a white solid.
4-(4-benzamidophenoxy)-N-methylpicolinamide (5o), Yield 78.1%; mp 180–182 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 7.17 (1H, q, Ar-H), 7.22–7.26 (2H, m, Ar-H), 7.40 (1H, d, J = 2.8 Hz, Ar-H), 7.53–7.57 (2H, m, Ar-H), 7.59–7.64 (1H, m, Ar-H), 7.91–7.95 (2H, m, Ar-H), 7.96–7.99 (2H, m, Ar-H), 8.52 (1H, d, J = 5.6 Hz, Ar-H), 8.79 (1H, q, NHCH3), 10.42 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.5, 109.3, 114.6, 121.8 (2C), 122.9 (2C), 122.9, 126.7, 130.7, 134.6, 136.6, 137.0, 148.2, 149.6, 150.8, 152.9, 163.8, 164.2, 166.2 ppm; ESI-MS: m/z 346.17 [M − H+].
N-methyl-4-(4-(2-(trifluoromethyl) benzamido) phenoxy) picolinamide (5p), Yield 92.0%; mp 178 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ:2.79 (3H, d, J = 4.8 Hz, CH3), 7.17 (1H, dd, J = 5.6, 2.4 Hz, Ar-H), 7.24 (2H, d, J = 7.6Hz, Ar-H), 7.40 (1H, d, J = 2.4 Hz, Ar-H), 7.71–7.76 (2H, m, Ar-H), 7.80–7.88 (4H, m, Ar-H), 8.51 (1H, d, J = 5.6 Hz, Ar-H), 8.78 (1H, q, CONH), 10.73 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.5 109.3, 114.5, 121.9 (2C), 122.9 (2C), 125.6, 126.2, 126.5, 129.0, 130.6, 133.1, 136.6, 137.2, 149.4, 150.9, 153.0, 164.2, 166.1, 166.3 ppm; ESI-MS: m/z 414.2 [M − H+].
N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenoxy) picolinamide (5q), Yield 95.0%; mp 152–153 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 7.18 (1H, q, Ar-H), 7.26 (2H, d, J = 8.8 Hz, Ar-H), 7.40 (1H, d, J = 2.4 Hz, Ar-H), 7.79–7.83 (1H, m, Ar-H), 7.91 (2H, d, J = 9.2 Hz, Ar-H), 7.99 (1H, d, J = 8.0 Hz, Ar-H), 8.27–8.30 (2H, m, Ar-H), 8.52 (1H, d, J = 5.6 Hz, Ar-H), 8.79 (1H, q, NHCH3), 10.63 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.4, 109.3, 114.6, 121.7 (2C), 122.8 (2C), 124.7, 124.8, 125.8, 128.6, 130.2, 132.3, 136.2, 137.1, 149.6, 150.8, 153.0, 164.2, 164.6, 166.3 ppm; ESI-MS: m/z 416.2 [M + H+].
N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenoxy) picolinamide·p-toluenesul fonic acid (5q·TsOH), Yield 95.0%; mp202–203 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.29 (3H, s, Ar-CH3), 2.81 (3H, d, J = 4.4 Hz, N-CH3), 6.30 (1H, s, SO3H), 7.13 (2H, d, J = 7.6 Hz, Ar-H), 7.25–7.30 (3H, m Ar-H), 7.48–7.54 (3H, m, Ar-H), 7.80–7.84 (1H, m, Ar-H), 7.94 (2H, d, J = 8.8 Hz, Ar-H), 8.00 (1H, d, J = 8.0 Hz, Ar-H), 8.28–8.31 (2H, m, Ar-H), 8.57 (1H, d, J = 6.0 Hz, Ar-H), 8.94 (1H, d, J = 5.2 Hz, NHCH3), 10.66 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 21.0, 26.6, 111.0, 114.9, 121.4 (2C), 122.7 (2C), 124.6, 125.8 (2C), 128.5 (2C), 129.0, 129.3, 129.6, 130.0, 132.1, 135.8, 137.6, 138.5, 145.1, 147.6, 148.4, 148.6, 161.1, 164.4, 169.1 ppm. ESI-MS: m/z 416.13 [M + H+]. IR 3341.6 cm−1, 3293.4 cm−1 (vN-H, CONH), 3107.5 cm−1, 3062.8 cm−1, 3032.9 cm−1 (v = C-H, Ar-H), 2809.4 cm−1, 2717.2 cm−1 (vN-H, > N+H2), 1693.3 cm−1(v as N-C=O, CONH), 1675.7 cm−1, 1547.1 cm−1 (v N-C=O, CONH), 1594.3 cm−1 (vC=C, Pyridine), 1615.8 cm−1, 1504.0 cm−1 (vC=C, phenyl), 1320.2 cm−1 (vC-F, ph-CF3), 1149.1 cm−1, 1123.6 cm−1 (vC-F, ph-CF3), 1194.3 cm−1 (vS=O, -SO3), 1032.3 cm−1, 1009.2 cm−1 (vS-O, -SO3), 847.9 cm−1, 824.5 cm−1, 700.0 cm−1 (δC-H, Ar-H), 568.7 cm−1, 558.7 cm−1 (δC-F,-CF3).
N-methyl-4-(4-(4-(trifluoromethyl) benzamido) phenoxy) picolinamide (5r), Yield 93.2%; mp 200 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 7.18 (1H, dd, J = 5.6, 2.4 Hz, Ar-H), 7.26 (2H, d, J = 8.8 Hz, Ar-H), 7.41 (1H, d, J = 2.4 Hz, Ar-H), 7.92–7.95 (4H, m, Ar-H), 8.17 (2H, d, J = 7.6 Hz, Ar-H), 8.53 (1H, d, J = 5.6 Hz, Ar-H), 8.79 (1H, q, NHCH3), 10.63 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.4, 109.3, 114.6, 121.8 (2C), 121.9 (2C), 125.7, 125.8, 126.4, 129.1, 131.1, 131.8, 137.1, 139.1, 149.5, 150.9, 153.0, 164.2, 164.9, 166.3 ppm; ESI-MS: m/z 414.2 [M − H+].
4-(4-(3- fluorobenzamido) phenoxy)-N-methylpicolinamide (5s), Yield 79.2%; mp 218–219 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 7.18 (1H, dd, J = 5.6, 2.8 Hz, Ar-H), 7.23–7.27 (2H, m, Ar-H), 7.40 (1H, d, J = 2.8 Hz, Ar-H), 7.45–7.50 (1H, m, Ar-H), 7.59–7.64 (1H, m, Ar-H), 7.78–7.84 (2H, m, Ar-H), 7.90–7.94 (2H, m, Ar-H), 8.52 (1H, d, J = 5.6 Hz, Ar-H), 8.79 (1H, q, NHCH3), 10.48 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.0, 108.8, 114.0, 121.2 (2C), 122.2 (2C), 123.9, 123.9, 130.5, 130.6, 136.7, 137.1, 137.1, 148.9, 150.3, 152.4, 163.7, 164.2, 165.8 ppm; ESI-MS: m/z 364.07 [M − H+].
4-(4-(3- chlorobenzamido) phenoxy)-N-methylpicolinamide (5t), Yield 75.1%; mp 168 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 7.18 (1H, q, Ar-H), 7.25 (2H, d, J = 9.2 Hz, Ar-H), 7.40 (1H, d, J = 2.8 Hz, Ar-H), 7.57–7.61 (1H, m, Ar-H), 7.68–7.70 (1H, m, Ar-H), 7.90–7.95 (3H, m, Ar-H), 8.03 (1H, t, J = 2.0 Hz, Ar-H), 8.52 (1H, d, J = 5.6 Hz, Ar-H), 8.79 (1H, q, NHCH3), 10.51 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.0, 108.8, 114.1, 121.2 (2C), 122.2 (2C), 126.5, 127.4, 130.4, 131.4, 133.2, 136.7, 136.8, 149.0, 150.4, 152.4, 163.7, 164.1, 165.8 ppm; ESI-MS: m/z 380.05 [M − H+].
N-methyl-4-(4-(3-nitrobenzamido) phenoxy) picolinamide (5u), Yield 75.3%; mp 204 °C; brown solid; 1H-NMR (400 MHz, DMSO-d6) δ: 2.79 (3H, d, J = 4.8 Hz, CH3), 7.19 (1H, dd, J = 5.6, 2.8 Hz, Ar-H), 7.26–7.30 (2H, m, Ar-H), 7.41 (1H, d, J = 2.4 Hz, Ar-H), 7.85–7.89 (1H, m, Ar-H), 7.91–7.95 (2H, m, Ar-H), 8.42–8.48 (2H, m, Ar-H), 8.53 (1H, d, J = 5.6 Hz), 8.78–8.82 (2H, m, Ar-H), 10.74 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 26.5, 109.3, 114.6, 121.8 (2C), 122.9 (2C), 122.9, 126.7, 130.6, 134.6, 136.6, 137.0, 148.2, 149.6, 150.8, 152.9, 163.8, 164.2, 166.2 ppm; ESI-MS: m/z 391.07 [M − H+].
4-(4-(cyclohexanecarboxamido) phenoxy)-N-methylpicolinamide (5v), Yield 72.5%; mp 176–177 °C; white solid; 1H-NMR (400 MHz, DMSO-d6) δ: 1.18–1.33 (3H, m, cyclohexane-H), 1.38–1.47 (2H, m, cyclohexane-H), 1.66 (1H, d, J = 10.8 Hz, cyclohexane-H), 1.75–1.83 (4H, m, cyclohexane-H), 2.30–2.37 (1H, m, cyclohexane-H), 2.78 (3H, d, J = 4.8 Hz, CH3), 7.12–7.17 (3H, m, Ar-H), 7.36 (1H, d, J = 2.0 Hz, Ar-H), 7.71–7.75 (2H, m, Ar-H), 8.50 (1H, d, J = 5.6 Hz, Ar-H), 8.77 (1H, q, NHCH3), 9.97 ppm (1H, s, CONH); 13C-NMR (100 MHz, DMSO-d6) δ: 25.2 (2C), 25.4, 26.0 (2C), 29.1, 44.8, 108.7, 113.9, 120.8 (2C), 121.2 (2C), 137.3, 148.1, 150.3, 152.4, 163.7, 165.9, 174.3 ppm; ESI-MS: m/z 352.24 [M − H+].

3.2. Pharmacology

3.2.1. Cell Culture

HepG2(ATCC® HB-8065™), HCT116(ATCC® CCL-247™), and CT26 (ATCC® CRL-2638™) cell lines were obtained from ATCC (Rockville, MD, USA). All experiments were performed in plastic flasks, dishes, and multi-well plates obtained from Costar, USA. Cells were cultured at 37 °C in a humidified atmosphere in the presence of 5% CO2. For routine maintenance, cells were cultured in 75 cm2 flasks containing RPMI medium 1640 or DMEM (Gibco BRL) supplemented with 10% (v/v) heat-inactivated fetal bovine serum, and containing standard concentrations of L-glutamine, penicillin, and streptomycin (Gibco BRL). Cells were harvested by trypsinization (0.05% (w/v) trypsin, 0.53 mM EDTA4Na) twice a week.

3.2.2. MTT

Cellular survival was evaluated by the MTT method [28]. Briefly, cells (3000/well) were seeded in 96-well plates and cultured for 24 h, followed by treatment with the compounds for 48 h. Ten microliters of 10 mg/mL MTT was added per well and incubated for another 2 h at 37 °C. Then, the supernatant fluid was removed and 150 μL/well DMSO was added for 15–20 min. The absorbance (OD) of each well was measured at 570 nm, using a SpectraMAX M5 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). The effect of compounds on tumor cell viability was expressed by the IC50 of each cell line.

3.2.3. Mice Tumor Models and Treatment

The animal experiment was performed in female Balb/c mice (8 weeks of age) with six mice per group, provided by the Center of Experimental Animals, Sichuan University (Chengdu, China). They were treated and executed in accordance with the protocols approved by the Animal Use and Care Committee, West China Hospital, Sichuan University. When the tumor became palpable about 10 days after subcutaneous inoculation into the right flank of Blab/c mice, 5q (10 mg/mL, dissolved in oil/water emulsion composed of 50% water, 45% peanut oil, 5% Tween80, and 0.5% CMC) was administered through gastric perfusion daily at a dosage of 75 mg/kg. Tumor diameters were measured once on another day. The volume of tumor was calculated by the following formula: volume (mm3) = long diameter (mm) × short diameter (mm)2 × 0.5236.

3.2.4. Histological Analysis

Immunohistochemistry was performed as follows. Briefly, 4% paraformaldehyde-fixed, paraffin-embedded sections or frozen sections from tumor tissues were incubated with a monoclonal rabbit anti-mouse CD31, at a 1:300 to 1:100 dilution (Santa Cruz) at 4 °C overnight. Following washes in PBS, the secondary antibody, biotinylated goat anti-rabbit antibody at a 1:1000 dilution (Vector), was added. The sections were then stained with streptavidin biotin reagents (Vector). Vessel density was determined by counting the number of microvessels per high-power field in the section with an antibody reactive to CD31. The TUNEL Kit (Promega) is based on the enzymatic addition of digoxigenin-nucleotide to the nicked DNA by terminal deoxynucleotidyl transferase. Sections in HE staining and immunohistochemical staining were observed by two pathologists in a blinded manner.

4. Conclusions

In summary, a series of new 4-(4-formamidophenylamino)-N-methylpicolinamide derivatives were synthesized and evaluated for their biological activities. Experiments in vitro showed that most of the derivatives could inhibit the proliferation of two kinds of human cancer cell lines (HepG2, HCT116) at low micromolar concentrations in a dose-dependent manner. Preliminary structure–activity relationships were put forward based on the biological results. Compound 5q was a promising agent, which significantly inhibited colon cancer growth in vivo with the suppression rate ranging from 70% to 90%. Inhibition of angiogenesis and apoptosis of cancer cells were also observed. The results suggest that 5q is a potential new small-molecule antitumor agent in chemotherapy for colon carcinoma. Further structural optimization and mechanism studies are worth pursuing.

Supplementary Materials

The following are available online. 1H-NMR, 13C-NMR, FT-IR and ESI-MS spectra of 5q·TsOH are available online. 1H-NMR spectra of 5a–v and 4a are also provided as Supplementary Materials.

Author Contributions

Methodology, N.M., S.Z. and M.H.; software, Y.Z. (Youzhi Xu), Y.Z. (Yong Xia) and X.Z.; writing—original draft preparation, N.M. and S.Z.; project administration, L.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National S&T Major Special Project on Major New Drug Innovations, grant number 2018ZX09201018.

Institutional Review Board Statement

All animal experiments in this study were performed in strict accordance with the regulations of the Animal Care and Use Committee of Sichuan University.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in supplementary materials.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 5a–5v are not available from the authors.

References

  1. Torre, L.A.; Siegel, R.L.; Ward, E.M.; Jemal, A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol. Biomark. Prev. 2016, 25, 16–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Evan, G.I.; Vousden, K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411, 342–348. [Google Scholar] [CrossRef]
  3. Viallard, C.; Larrivee, B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis 2017, 20, 409–426. [Google Scholar] [CrossRef]
  4. Sajib, S.; Zahra, F.T.; Lionakis, M.S.; German, N.A.; Mikelis, C.M. Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions. Angiogenesis 2018, 21, 1–14. [Google Scholar] [CrossRef] [PubMed]
  5. Ferguson, F.M.; Gray, N.S. Kinase inhibitors: The road ahead. Nat. Rev. Drug Discov. 2018, 17, 353–377. [Google Scholar] [CrossRef] [PubMed]
  6. Du, Z.; Lovly, C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 2018, 17, 58. [Google Scholar] [CrossRef]
  7. Folkman, J.; Long, D.M., Jr.; Becker, F.F. Growth and metastasis of tumor in organ culture. Cancer 1963, 16, 453–467. [Google Scholar] [CrossRef]
  8. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 2005, 438, 967–974. [Google Scholar] [CrossRef]
  9. Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A.A.; Albert, D.H.; Bauch, J.L.; Bouska, J.J.; Bousquet, P.F.; Cunha, G.A.; Glaser, K.B.; et al. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N’-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem. 2007, 50, 1584–1597. [Google Scholar] [CrossRef]
  10. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J.Y.; Chu, J.Y.; Nematalla, A.; Wang, X.; et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46, 1116–1119. [Google Scholar] [CrossRef] [PubMed]
  11. Pietras, K.; Rubin, K.; Sjoblom, T.; Buchdunger, E.; Sjoquist, M.; Heldin, C.H.; Ostman, A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002, 62, 5476–5484. [Google Scholar]
  12. Potashman, M.H.; Bready, J.; Coxon, A.; DeMelfi, T.M., Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; et al. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem. 2007, 50, 4351–4373. [Google Scholar] [CrossRef] [PubMed]
  13. Lindahl, P.; Johansson, B.R.; Leveen, P.; Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277, 242–245. [Google Scholar] [CrossRef]
  14. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat. Rev. Drug. Discov. 2006, 5, 835–844. [Google Scholar] [CrossRef]
  15. Spano, J.P.; Chodkiewicz, C.; Maurel, J.; Wong, R.; Wasan, H.; Barone, C.; Letourneau, R.; Bajetta, E.; Pithavala, Y.; Bycott, P.; et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 2008, 371, 2101–2108. [Google Scholar] [CrossRef]
  16. Oh, Y.; Herbst, R.S.; Burris, H.; Cleverly, A.; Musib, L.; Lahn, M.; Bepler, G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J. Clin. Oncol. 2008, 26, 1135–1141. [Google Scholar] [CrossRef]
  17. Demetri, G.D.; van Oosterom, A.T.; Garrett, C.R.; Blackstein, M.E.; Shah, M.H.; Verweij, J.; McArthur, G.; Judson, I.R.; Heinrich, M.C.; Morgan, J.A.; et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368, 1329–1338. [Google Scholar] [CrossRef]
  18. Deremer, D.L.; Ustun, C.; Natarajan, K. Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Ther. 2008, 30, 1956–1975. [Google Scholar] [CrossRef] [PubMed]
  19. Medina, P.J.; Goodin, S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 2008, 30, 1426–1447. [Google Scholar] [CrossRef]
  20. Zeng, X.X.; Zheng, R.L.; Zhou, T.; He, H.Y.; Liu, J.Y.; Zheng, Y.; Tong, A.P.; Xiang, M.L.; Song, X.R.; Yang, S.Y.; et al. Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: Synthesis, preliminary structure-activity relationships, and in vitro biological evaluation. Bioorg. Med. Chem. Lett. 2010, 20, 6282–6285. [Google Scholar] [CrossRef]
  21. Wen, J.; Fu, A.F.; Chen, L.J.; Xie, X.J.; Yang, G.L.; Chen, X.C.; Wang, Y.S.; Li, J.; Chen, P.; Tang, M.H.; et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. J. Cancer 2009, 124, 2709–2718. [Google Scholar] [CrossRef]
  22. Luo, Y.; Xu, Y.; Chen, L.; Hu, J.; Peng, C.; Xie, D.; Shi, J.; Huang, W.; Xu, G.; Peng, M.; et al. Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol. Bioorg. Med. Chem. Lett. 2009, 19, 4702–4705. [Google Scholar] [CrossRef] [PubMed]
  23. Yu, L.; Zhao, Y.; Wei, Y.; Yang, S.; Yang, L. 4-(4-aminoanilino)-2-(methylcarbamoyl) Pyridine and Its Derivatives, and Their Preparation Method and Application. CN 101362717A, 2 November 2009. [Google Scholar]
  24. Yu, L.; Zhao, Y.; Wei, Y.; Yang, S.; Yang, L. 4-(4-benzoylaminophenoxy)-2-(methylcarbamoyl) Pyridine and Its Derivatives, and Their Preparation Method and Application. CN 101362718A, 2 November 2009. [Google Scholar]
  25. Anchoori, R.K.; Kortenhorst, M.S.; Hidalgo, M.; Sarkar, T.; Hallur, G.; Bai, R.; Diest, P.J.; Hamel, E.; Khan, S.R. Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy. J. Med. Chem. 2008, 51, 5953–5957. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Michael, L.; Reinhold, G.; Oliver, K.; Mike, M.; Klaus, M.; Matthias, M.G.; Jurjen, S.; Mathias, B.; Jana, L.; Wernner, H. Procede de Preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxa-mide. PCT Int. Appl. WO 2006034796 A1, 6 April 2006. [Google Scholar]
  27. Bankston, D.; Dumas, J.; Natero, R.; Riedl, B.; Monahan, M.K.; Sibley, R. A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer. Org. Process. Res. Dev. 2002, 6, 777–781. [Google Scholar] [CrossRef]
  28. Cao, Z.; Zhen, R.; Lin, H.; Luo, S.; Zhou, Y.; Xu, Y.; Zeng, X.; Wang, Z.; Zhou, L.; Mao, Y.; et al. SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo. Cell. Physiol. Biochem. 2011, 27, 565–574. [Google Scholar] [CrossRef]
Molecules 26 01150 sch001 550
Scheme 1. Synthesis of compounds 5a–5v. Reagent and conditions: (a) chlorobenzene, sodium bromide, and thionyl chloride reflux for 19 h, 85 °C; (b) 25% methylamine aqueous, THF; (c) 4a: (i) N-(4-aminophenyl)acetamide, 160 °C, (ii) EtOH, concentrated HCl, reflux for 4 h; 4b: 4-aminophenol, sodium hydride, DMSO, 100 °C, stir for 3 h; (d) triphosgene, substituted aniline or cyclohexylamine, triethylamine, and CH2Cl2 reflux for 1 h; (e) K2CO3, THF, substituted benzoyl chloride, r.t.
Scheme 1. Synthesis of compounds 5a–5v. Reagent and conditions: (a) chlorobenzene, sodium bromide, and thionyl chloride reflux for 19 h, 85 °C; (b) 25% methylamine aqueous, THF; (c) 4a: (i) N-(4-aminophenyl)acetamide, 160 °C, (ii) EtOH, concentrated HCl, reflux for 4 h; 4b: 4-aminophenol, sodium hydride, DMSO, 100 °C, stir for 3 h; (d) triphosgene, substituted aniline or cyclohexylamine, triethylamine, and CH2Cl2 reflux for 1 h; (e) K2CO3, THF, substituted benzoyl chloride, r.t.
Molecules 26 01150 sch001
Molecules 26 01150 g001 550
Figure 1. Effects of 5q on tumor-bearing mice. 5q was orally administered to Balb/c mice through gastric perfusion daily at a dosage of 75 mg/kg about 10 days after inoculation of cells. The volume of tumor was calculated by the following formula: volume (mm3) = long diameter (mm) × short diameter (mm)2 × 0.5236. (A) Oral treatment with 5q presents a decrease in tumor volume against untreated (p < 0.05). (B) H&E staining of tumor tissue sections of untreated group (a), 5q-treated group (b) (400×). (C) Oral treatment with 5q presents a survival advantage against untreated. Data are plotted as the percentage of survival animal.
Figure 1. Effects of 5q on tumor-bearing mice. 5q was orally administered to Balb/c mice through gastric perfusion daily at a dosage of 75 mg/kg about 10 days after inoculation of cells. The volume of tumor was calculated by the following formula: volume (mm3) = long diameter (mm) × short diameter (mm)2 × 0.5236. (A) Oral treatment with 5q presents a decrease in tumor volume against untreated (p < 0.05). (B) H&E staining of tumor tissue sections of untreated group (a), 5q-treated group (b) (400×). (C) Oral treatment with 5q presents a survival advantage against untreated. Data are plotted as the percentage of survival animal.
Molecules 26 01150 g001
Molecules 26 01150 g002 550
Figure 2. 5q induces the apoptosis of cancer cells and inhibits angiogenesis. (A) 5q induces the apoptosis of cancer cells. (a) Scattered positive signals in the control group. (b) Clustered positive signals in 5q-treated group. (B) Quantitative analysis of the apoptotic cells. Data are represented as means ± standard deviation of cells per hpf (* p < 0.05) (200×). (C) 5q inhibits angiogenesis. CD31 immunohistochemistry in the frozen sections from the control group (a) and 5q-treated group (b). (D) Quantitative analysis of the vessel density. Data are represented as means ± standard deviation of vessels per hpf (* p < 0.05) (200×).
Figure 2. 5q induces the apoptosis of cancer cells and inhibits angiogenesis. (A) 5q induces the apoptosis of cancer cells. (a) Scattered positive signals in the control group. (b) Clustered positive signals in 5q-treated group. (B) Quantitative analysis of the apoptotic cells. Data are represented as means ± standard deviation of cells per hpf (* p < 0.05) (200×). (C) 5q inhibits angiogenesis. CD31 immunohistochemistry in the frozen sections from the control group (a) and 5q-treated group (b). (D) Quantitative analysis of the vessel density. Data are represented as means ± standard deviation of vessels per hpf (* p < 0.05) (200×).
Molecules 26 01150 g002
Table
Table 1. The antiproliferation activities of compounds 5a–v against HepG2 and HCT116.
Table 1. The antiproliferation activities of compounds 5a–v against HepG2 and HCT116.
Molecules 26 01150 i001
CompoundXYRIC50(μM) 1
HepG2HCT116
5aNHNHCONHPh-48.4 ± 2.528.2 ± 1.6
5bNHNHCONH3-CF3-Ph-16.8 ± 2.014.9 ± 1.1
5cNHNHCONH3-F-Ph-40.0 ± 3.118.1 ± 1.0
5dNHNHCONH3-Cl-Ph-22.4 ± 1.421.0 ± 1.1
5eNHNHCONH3-Br-Ph-18.0 ± 1.217.2 ± 1.2
5fNHNHCONH3-NO2-Ph-24.1 ± 1.327.6 ± 1.6
5gNHNHCONH3-MeO-Ph-27.6 ± 1.717.1 ± 0.8
5hNHNHCONH4-Cl-3-CF3-Ph-25.2 ± 1.329.2 ± 1.3
5iNHNHCONHcyclohexane-17.3 ± 1.012.1 ± 0.7
5jNHCONH3-CF3-Ph-16.8 ± 1.131.5 ± 1.9
5kNHCONH3-F-Ph-60.2 ± 3.417.9 ± 1.2
5lNHCONH3-Cl-Ph-94.4 ± 3.925.6 ± 1.4
5mNHCONH3-NO2-Ph->100>100
5nNHCONH3-MeO-Ph-32.2 ± 2.029.2 ± 1.9
5oOCONHPh-55.1 ± 3.261.6 ± 3.1
5pOCONH2-CF3-Ph->10098.0 ± 4.2
5qOCONH3-CF3-Ph-6.6 ± 0.35.3 ± 0.3
5rOCONH4-CF3-Ph-51.4 ± 2.848.8 ± 3.2
5sOCONH3-F-Ph->10056.2 ± 3.8
5tOCONH3-Cl-Ph-68.2 ± 3130.6 ± 2.8
5uOCONH3-NO2-Ph->100>100
5vOCONHcyclohexane->10055.8 ± 4.1
Sorafenib 2 15.3 ± 0.813.1 ± 0.7
1 The cytotoxicity effects of various compounds were determined by the MTT assay, and the results were expressed as the mean IC50 calculated from three independent experiments. 2 We select Sorafenib as the reference compound based on its structural similarity.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Meng, N.; Zhou, S.; Hu, M.; Xu, Y.; Xia, Y.; Zeng, X.; Yu, L. Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents. Molecules 2021, 26, 1150. https://doi.org/10.3390/molecules26041150

AMA Style

Meng N, Zhou S, Hu M, Xu Y, Xia Y, Zeng X, Yu L. Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents. Molecules. 2021; 26(4):1150. https://doi.org/10.3390/molecules26041150

Chicago/Turabian Style

Meng, Nana, Shuyan Zhou, Min Hu, Youzhi Xu, Yong Xia, Xiuxiu Zeng, and Luoting Yu. 2021. "Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents" Molecules 26, no. 4: 1150. https://doi.org/10.3390/molecules26041150

Article Metrics

Back to TopTop